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The protic and Lewis acid promoted cyclization reactions of tethered furan-4,5-dihydroxypiperid-2-ones, 
furan-4,5-diacetoxypiperid-2-ones and furan-3,4-diacetoxypyrrolid-2-ones, via their corresponding N-
acyliminium ion intermediates, have been studied. In the case of the furan-4,5-dihydroxypiperid-2-one 2a 
and its diacetate derivative 2b, macrocyclic products were formed from an initial intermolecular reaction 
between 2a or 2b, via the nucleophilic C5 furan carbon, and their corresponding N-acyliminium ion 
intermediates. When the furan C5 position of 2b was blocked by substitution with bromine then TFA or 
Sc(OTf)3 catalysed cyclization reactions gave a spirotricyclic product (a 5-6-6-tricycle) in a highly 
diastereoselective manner. Cyclization of the analogous C5-Br-furan-pyrrolidone 29 with TFA resulted in a 
related spirotricyclic (a 5-6-5 tricycle) product. Attempts to prepare an analogous azepine system, a 5-7-5 
tricycle, were not successful. Cyclization reactions of the C5-PhS-furan- or C5-phenylsulfonyl-pyrrolidone 
analogues of 29 with TFA were also not successful. 
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The protic and Lewis acid promoted cyclization reactions of tethered furan-4,5-
dihydroxypiperid-2-ones, furan-4,5-diacetoxypiperid-2-ones and furan-3,4-
diacetoxypyrrolid-2-ones, via their corresponding N-acyliminium ion intermediates, 
have been studied. In the case of the furan-4,5-dihydroxypiperid-2-one 2a, and its 
diacetate derivative 2b, macrocyclic products were formed from an initial intermolecular 
reaction between 2a or 2b, via the nucleophilic C5 furan carbon, and their corresponding 
N-acyliminium ion intermediates. When the furan C5 position of 2b was blocked by 
substitution with bromine then TFA or Sc(OTf)3 catalysed cyclization reactions gave a 
spirotricyclic product (a 5-6-6-tricycle) in a highly diastereoselective manner. 
Cyclization of the analogous C5-Br-furan-pyrrolidone 29 with TFA resulted in a related 
spirotricyclic (a 5-6-5 tricycle) product. Attempts to prepare an analogous azepine 
system, a 5-7-5 tricycle, were not successful. Cyclization reactions of the C5-PhS-furan- 





As part of a study aimed at the synthesis of the pyrido[1,2-a]azepine, Stemona alkaloid, 
stemocurtisine 11 (Figure 1) we have investigated the cyclization reactions of the 
tethered furan-piperidones 2a-c via generation of the corresponding N-acyliminium ion 













Figure 1. The structure of stemocurtisine 1 
 
These reactions could in principle give either the linearly fused tricyclic furan system 6, 
with the desired A-B-C-ring structure of stemocurtisine 1, or the spirocyclic products 7, 
via the carbocationic intermediates 4 and 5, respectively (Scheme 1). The intermediate 4 
would be stabilized by the furan oxygen while the spirocyclic intermediate 5 would be 
stabilized by the furan substituent X, when X was an electron donating group, and 
destabilized when X was an electron withdrawing group. Consistent with this 
mechanistic scheme are the studies by Martin3 and Tanis4. Martin found that the LiClO4 
promoted cyclization reactions of the highly activated TIPSO substituted furan 
substrates 8 gave exclusively the spirotricyclic products 9a,b (Scheme 2) while Tanis 
disclosed the formation of linearly fused tricyclic adducts 11a,b from substrates 10 in 
which the furan ring was only substituted at the tethered position (Scheme 3). 
Unfortunately, attempts by the latter group to prepare an azepine system 12b, as desired 
by us, were unsuccessful (Scheme 3). However, a more recent report by Padwa showed 
that the formation of the azepine ring of 14 was possible employing a tethered 4-ethyl 
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substituted furan 13 (Scheme 4).5 With this information in mind we decided to 
investigate the effect of various substituents on the furan ring on the cyclization 

































The furyl amine 17, that was required for the synthesis of 2a, was synthesized from 
commercially available nitrile 15 in 81% yield over two steps as shown in Scheme 5.6 
Amine 17 was coupled with the acid chloride prepared from L-glutamic acid7 to give 
amide 18 in 80% yield. Potassium tert-butoxide catalysed rearrangement of 18 provided 
glutarimide 19 in high yield (90%).8 The C2 carbonyl group of 19 was regioselectively 
reduced using NaBH4 to give the diol 2a.
9 With the cyclization precursor in hand we 
further subjected 2a to various Lewis acid or acid catalysed reaction conditions. Long 
exposure of 2a to excess amounts of BF3·Et2O or TFA resulted in the formation of 
complex reaction mixtures with no traces of the requisite tricyclic products. However, 
treatment of 2a with one equiv. of TFA in CH2Cl2 solution at rt for 2 h resulted in the 
self condensation product 20 as a single diastereomer in 54% yield (Scheme 6). 
Compound 20 had C2 symmetry and was mostly likely formed from a dimerization 
reaction of the N-acyliminium ion intermediate A. While we did not comprehensively 
prove the stereochemistry of 20 the 1H NMR coupling constant J4a,10a of 3.1 Hz 
suggested that the rings were cis-fused. When 2a was treated with 1 equiv. of BF3·Et2O 
at rt for 2 d the macrocycle 21 was isolated in 29% yield after purification by column 
chromatography (Scheme 7). In this case, the furan moiety of 2a acted as a nucleophile, 
in an intermolecular sense at C5, with the N-acyliminium ion A. While 20 was also 
likely to be formed initially in this reaction it would be expected to be in equilibrium 
with the N-acyliminium ion A and thus 20 would be slowly transformed into the more 
stable product 21. Our attempts to achieve the transformation of 20 to 21, however, were 
not successful. For example, exposure of 20 to BF3·Et2O resulted in a complex mixture 
of products. The yield of this macrocycle forming reaction was found to be better when 
carried out on the diacetate derivative 2b. This substrate gave the macrocycle 22 in 58% 
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yield upon treatment with one equiv. of BF3·Et2O at rt for 16 h. Base catalysed 
hydrolysis of the acetate groups of 22 gave the same macrocycle 21, in 98% yield, that 
was obtained from the reaction of 2a (Scheme 7). The stereochemistry of 21 was 
assigned as trans based on its 1H NMR coupling constant, J5-6 (2.7 Hz), which is 
consistent in magnitude with that of related trans 5,6–disubstituted glutaramide 
derivatives.9 The formation of the macrocycles 21 and 22, rather than the desired linear 
tricyclic products similar to 12b, (Scheme 3) is consistent with the results of Tanis4 who 
found that formation of an azepine ring in an intramolecular sense was unrewarding in 
such types of reactions. Clearly in our case intermolecular reactions are more 
favourable. Formation of similar macrocycles have been previously reported by Padwa 




































Reagents and conditions: (a) Pd/C, H2, EtOH, rt, 16 h, 88% (b) LiAlH4, THF, 0 °C, 1 h, 
92% (c) acid chloride, TEA, CH2Cl2, rt, 16 h, 80% (d) tert-BuOK, THF, -78 °C to -40 






































Reagents and conditions: (a) BF3·Et2O (1 eq.), MeCN, rt, 2 days, 29% (b) Ac2O, 
pyridine, DMAP, 20 h, 98% (c) BF3·Et2O (1 eq.), MeCN, rt, 16 h, 58% (d) KOH, 
MeOH, rt, 16 h, 98% 
 
To avoid intermolecular reactions and thus favour intramolecular cyclization, we 
synthesized the cyclization precursor 2c, in which both the potentially nucleophilic sites, 
the C5-hydroxyl group on the piperidinone ring and the C5 position on the furan ring 
were protected and blocked, respectively. We chose to block the C5 position of the furan 
moiety with bromine hoping that this weak electron withdrawing group would not 
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dramatically reduce the nucleophilicity of the furan towards cyclization. Thus compound 
19 was treated with NBS in DMF10 to give the corresponding bromo-furan 23 in 62% 
yield (Scheme 8). Regioselective carbonyl reduction of 23 using NaBH4 gave the diol 
24, which was further protected by acetate groups giving 2c. Compound 2c when treated 
with TFA (3 equiv.) gave the spirocyclic butenolide 25 as a single diastereoisomer in 
54% yield. A better yield (71%) of 25 was obtained when the reaction was carried out in 
the presence of scandium triflate (0.2 equiv.). In this study 25 was formed as a single 
diastereoisomer and we did not observe any products arising from cyclization at the C3 
position of the furan moiety. The stereochemistry of 25 was confirmed by a single 
crystal, X-ray crystallographic analysis which indicated the anti relationship between 
H1-H9a and between H9a and the butenolide oxygen (Figure 1). The formation of 25 is 
consistent with the formation of carbocation intermediate 5 (X = Br) which is resonance 
stabilized by the Br atom. These results obtained here are similar to those of Martin in 
terms of the mode of cyclization and the relative stereochemical outcome between H9a 
and the butenolide oxygen (Scheme 2).3  
We also investigated if this reaction could be used to synthesize a tricyclic spiro-
butenolide with a 5-6-5 tricyclic ring skeleton by subjecting the tethered furan-
pyrrolidinone 29 to acidic conditions. Compound 29 was synthesized in a similar way as 
2a, in this case starting with the furyl amine 17 and (S)-malic acid. Compound 29 when 
treated with 3 equiv. of TFA in CH2Cl2 at rt for 16 h formed the spirocyclic butenolide 
30 as a single diastereomer in 59% yield. The configuration of C8a was expected to be 
the same as that of C9a in 25. This was further supported by the magnitude of the 1H 
NMR coupling constant J8a,1 (1.3 Hz) which was consistent with the coupling constant 
observed for trans-4,5-disubstituted-pyrrolidinone derivatives.9 Based on the 
 
stereochemical outcomes 















24; R = H
b d or e
c
2c; R = Ac
Reagents and conditions: (a) 
Ac2O, Pyridine, DMAP, rt, 16 h, 76% (d) TFA, 
48 h, 71%. 
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observed by Martin3 (Scheme 2) and a strong correlation 
 the NOE spectrum of 30 we have assigned






























NBS, DMF, 0 °C, 1 h, 62% (b) NaBH4, EtOH, -30 °
CH2Cl2, rt, 16 h, 54 % (e) Sc(OTf)
 
 the trans 
. 
C, 2 h, 75% (c) 
3, MeCN, rt, 
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Figure 1. Molecular structure of compound 25 (C14H17NO5) with labelling of selected 
atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. Compound numbering is different to the 




Reagents and conditions: (a) (S)-malic acid, xylene, 180 °C, 1.5 h, 69% (b) NBS, DMF, 
0 °C, 1 h, 71% (c) NaBH4, EtOH, −20 °C, 1 h, 62% (d) Ac2O, pyridine, DMAP, rt, 16 h, 
82% (e) TFA, CH2Cl2, rt, 16 h, 59% 
 
Our attempts to preparing a spirocyclic 5-7-5 tricyclic ring structure using this 
methodology, akin to that found in many croomine-type Stemona alkaloids,11-14 have not 
been successful.15  
We further investigated the cyclization reactions of tethered furan-pyrrolidinones with 
an electron donating phenylthio and an electron withdrawing phenylsulfonyl group at the 
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C5 position of the furan ring. Target compounds 37 and 40 were synthesized from 
commercially available furyl nitrile 15 (Scheme 10). Bromination of 15 with NBS gave 
31 which on treatment with the sodium salt of thiophenol gave the thioether 32 in a 69% 
yield. Compound 33 was synthesized by reduction of double bond of 32 using a mixture 
of a NiCl2/NaBH4 in the presence of (Boc)2O,
16 in the anticipation of producing the N-
Boc derivative of 34, however, in our hands this only gave the conjugate reduction 
product 33. Further reduction of the nitrile 33 with LiAlH4 gave amine 34. Compound 
37 was synthesised from amine 34 in a similar fashion to the synthesis of 2c. For the 
synthesis of 40, the thioether 35 was oxidised with H2O2/HOAc giving sulfone 38 in 
excellent yield. The C2 carbonyl group of 38 was regioselectively reduced with NaBH4 
followed by acetate protection to give 40. Unfortunately neither compound 37 nor 40, 
when treated with TFA, gave any cyclization products and only their C5-
hydroxypyrrolidinone derivatives could be isolated. The results obtained with 37 were 
surprising since we thought that the electron donating thioether group would make the 
furan ring more nucleophilic and thus favour the cyclization reaction. These results 
suggest that the thio ether group may have been protonated under the acidic conditions 
and thus has acted as a deactivating group, much like the sulfone group in 40, resulting 
in no observed cyclization products. Indeed a 1H NMR spectrum of 37 in CDCl3 showed 
significant downfield shifts of the thiophenyl ortho and para proton resonances after the 














Reagents and conditions: (a) NBS, DMF, 0 °C, 1 h, 72% (b) PhSNa, MeOH, reflux, 16 h, 69% 
(c) NiCl2.6H2O, NaBH4, (Boc)2O, MeOH, rt, 16 h, 57% (d) LiAlH4, Et2O, 0 °C, 1h (e) (S)-malic 
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acid, xylene, 180 °C, 2 h, 39% (2 steps) (f) NaBH4, EtOH, −40 °C, 1h, 50% (g) Ac2O, pyridine, 
DMAP, 16 h, rt, 91% (h) TFA, CH2Cl2, rt, 3 days (i) H2O2, AcOH, rt, 2 days, 96% (j) NaBH4, 
EtOH, -40 °C, 1 h, 54% (k) Ac2O, pyridine, DMAP, rt, 16 h, 98%. 
3. Conclusions 
We have studied the protic and Lewis acid catalysed cyclization reactions of tethered 
furan-4,5-dihydroxypiperid-2-ones, furan-4,5-diacetoxypiperid-2-ones and furan-3,4-
diacetoxypyrrolid-2-ones via their corresponding N-acyliminium ion intermediates. In 
the case of the furan-piperidone 2a and its diacetate derivative 2b a macrocyclic product 
arose from an initial intramolecular reaction between 2a or 2b, via the nucleophilic C5 
furan carbon, and their corresponding N-acyliminium ion intermediates. When the furan 
C5 position of 2b was blocked by substitution with a bromine atom then TFA or 
Sc(OTf)3 catalysed cyclization gave a spirotricyclic product (a 5-6-6-tricycle) in a highly 
diastreoselective manner. The alternative cyclization product having the linearly fused 
tricyclic furan system required for the synthesis of stemocurtisine was not produced. 
Cyclization of the analogous C5-Br-furan-pyrrolidone 29 with TFA resulted in a related 
spirotricyclic (a 5-6-5 tricycle) product. Attempts to prepare an analogous azepine 
system, a 5-7-5 tricycle, were not successful. Cyclization reactions of the C5-PhS-furan-
pyrrolidone or C5-phenylsulfonyl analogues of 29 with TFA were also not successful. 




4.1 General  
All IR spectra were run as neat samples. All NMR spectra were run at 500 MHz (1H 
NMR) or 125 MHz (13C NMR) in solutions of CDCl3 unless otherwise noted. FCC is an 
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abbreviation for flash column chromatography. Petrol refers to the hydrocarbon fraction 
of bp 40-60 °C.  
4.2 3-(Furan-2-yl)propanenitrile (16).
17 
A solution of 15 (1.00 g, 8.40 mmol) in ethanol (10 mL) was flushed with N2 for 5 min. 
followed by addition of 10 % Pd on C (200 mg) and the reaction mixture was stirred for 
18 h under a H2 atmosphere (H2 balloons) at rt. The reaction mixture was filtered 
through celite, washed with ethanol (3 × 15 mL) and the solvent was removed under 
reduced pressure. The crude residue was purified by FCC over silica gel using a gradient 
of 0:100–12:88 EtOAc/petrol to give 16 as a colourless oil (894 mg, 88%). Rf: 0.48 
(10:90, EtOAc/petrol). 1H NMR δ 7.31 (bs, 1H), 6.28 (bs, 1H), 6.13 (d, 1H, J 3.2 Hz), 




To a mixture of lithium aluminium hydride (471 mg, 12.3 mmol) in THF (10 mL) at 0 
°C was added dropwise a solution of 16 (500 mg, 4.13 mmol) in THF (5 mL) under a N2 
atmosphere. The reaction mixture was stirred at the same temperature for 1 h. The 
reaction mixture was cooled to −10 °C followed by the dropwise addition of water (2 
mL) and 10 % NaOH (2 mL). The reaction mixture was slowly warmed to rt and then 
diluted with Et2O (20 mL), filtered through celite and the solids were washed several 
times with Et2O (3 × 10 mL). The filtrate was dried (MgSO4) and the solvent was 
removed under reduced pressure to give amine 17 as a thick colourless oil (516 mg, 92 
%); 1H NMR δ 7.22 (bs, 1H), 6.20 (bs, 1H), 5.92 (bs, 1H), 2.70−2.55 (m, 4H), 1.76−1.66 
(m, 2H). 
4.3 (R)-N-(3-(Furan-2-yl)propyl)-5-oxotetrahydrofuran-2-carboxamide (18). 
18 
 
To a solution of 17 (500 mg, 4.00 mmol) in CH2Cl2 (5 mL) was added triethylamine 
(1.11 mL, 8.00 mmol) and the reaction mixture was cooled to 0 °C. After 5 min. a 
solution of 5-oxotetrahydrofuran-2-carbonyl chloride (592 mg, 8.00 mmol) in CH2Cl2 (5 
mL) was added dropwise over 30 min. The reaction was then stirred at rt for 18 h. The 
reaction was quenched with water (5 mL) and extracted with CH2Cl2 (3 × 25 mL). The 
combined extracts were dried (MgSO4) and then the solvent was removed under reduced 
pressure. The residue obtained was purified by FCC over silica gel using a gradient of 
10:90−40:60 EtOAc/petrol to afford 18 as a colourless thick oil (758 mg, 80%); Rf: 0.31 
(25:75, EtOAc/petrol); [α] 25D
 -20.9 (c 1.1, CHCl3); IR vmax (cm
-1): 3341, 1778, 1650, 
1542, 1178, 1139, 1045, 741; 1H NMR δ 7.31 (bs, 1H), 6.47(bs, 1H), 6.30-6.36 (m, 1H), 
6.02 (d, 1H, J 3.3 Hz), 4.82 (t, 1H, J 7.4 Hz), 3.42−3.28 (m, 2H), 2.68 (t, 2H, J 7.4 Hz), 
2.65−2.58 (m, 1H), 2.55 (t, 2H, J 7.1 Hz), 1.89 (p, 2H, J 7.1 Hz);13C NMR δ 175.9, 
169.5, 154.8, 141.4, 110.4, 105.6, 77.3, 39.0, 27.9, 27.8, 26.0, 25.6. HRMS (ESI +ve) 
calculated for C12H16NO4 (M+H
+) 238.1074, found 238.1080.   
4.4 (S)-1-(3-(Furan-2-yl)propyl)-3-hydroxypiperidine-2,6-dione (19). 
Compound 18 (100 mg, 0.421 mmol) was dissolved in THF (5 mL) and the reaction 
mixture was cooled to −78 °C. Potassium tert-butoxide (24 mg, 0.210 mmol) was added 
over 10 min. in small portions to the reaction mixture. The reaction mixture was slowly 
warmed to −40 °C and stirred at the same temperature until TLC analysis showed 
completion of the reaction. The reaction mixture was cooled to −78 °C and then 
quenched with a saturated solution of NaHCO3 (2 mL). The reaction mixture was then 
diluted with water (5 mL) and then extracted with EtOAc (3 × 25 mL). The combined 
extracts were dried (MgSO4) and the solvent was removed under reduced pressure. The 
residue was purified by FCC using a gradient of 10:90–30:70 EtOAc/petrol to give 19 as 
19 
 
a white solid (90 mg, 90%); Rf: 0.62 (25:75, EtOAc/petrol); Mp: 78–82 °C; [α]
25
D
 -63 (c 
1.7, CHCl3); IR vmax (cm
-1): 3402, 1731, 1650, 1363, 1334, 1319, 1245, 1093, 1077, 
1035, 1007, 731; 1H NMR δ 7.28 (bs, 1H), 6.27 (bs, 1H), 6.02 (d, 1H, J 3.1 Hz), 4.16 
(dd, 1H, J 12.4, 5.7 Hz), 3.91−3.76 (m, 2H), 3.61 (bs, 1H), 2.89−2.81 (m, 1H), 2.65 (t, 
2H, J 7.3 Hz), 2.64−2.54 (m, 1H), 2.34−2.36 (m, 1H), 1.95-1.79 (m, 3H); 13C NMR δ 
175.2, 171.1, 154.9, 140.9, 110.1, 104.9, 68.2, 40.0, 30.7, 25.8, 25.5, 25.2; HRMS (ESI 
+ve) calculated for C12H16NO4 (M+H
+) 238.1074, found 238.1081.  
4.5 (5S)-1-(3-(Furan-2-yl)propyl)-5,6-dihydroxypiperidin-2-one (2a).  
Compound 19 (190 mg, 0.801 mmol) was dissolved in EtOH/CH2Cl2 (8:2, 5 mL) and 
the reaction mixture was cooled to −40 °C followed by addition of NaBH4 (213 mg, 5.61 
mmol) and the reaction mixture stirred at the same temperature for 1 h. The reaction was 
quenched with a saturated solution of NaHCO3 (5 mL) and the reaction mixture was 
warmed to rt. The reaction mixture was extracted with EtOAc (3 × 25 mL), and the 
combined extracts were dried (MgSO4) and the solvent was removed under reduced 
pressure. The residue was purified by FCC over silica gel using a gradient of 0:100–
10:90 MeOH/EtOAc to give 2a as a thick colourless liquid as a single diastereoisomer 
(90 mg, 47%); Rf: 0.43 (10:90, MeOH/EtOAc); [α]
25
D
 +18.6 (c 3.2, MeOH); IR vmax (cm
-
1): 3423, 2940, 1718, 1654, 1636, 1617, 1508, 1481, 1039, 740; 1H NMR (CD3OD) δ 
7.37 (bs, 1H), 6.27 (dd, 1H, J 3.0, 1.9 Hz), 6.04 (d, 1H, J 3.0 Hz), 4.73 (d, 1H, J 2.4 Hz), 
3.87-3.82 (m, 1H), 3.71-3.62 (m, 1H), 3.26-3.16 (m, 1H), 2.64 (t, 2H, J 7.5 Hz), 2.58-
2.49 (m, 1H), 2.31−2.24 (m, 1H), 2.21−2.12 (m, 1H), 1.95 (p, 2H, J 7.8 Hz), 1.80−1.73 
(m, 1H); 13C NMR δ 171.5, 155.5, 140.9, 109.9, 104.7, 83.6, 67.4, 44.9, 26.8, 26.1, 25.1, 
22.2; HRMS (ESI +ve) calculated for C12H18NO4 (M+H





To a solution of 2a (50 mg, 0.209 mmol) in CH2Cl2 (3 mL) was added TFA (0.032 mL, 
0.418 mmol) and the reaction mixture was stirred at rt for 2 h. The reaction mixture was 
quenched with a saturated solution of Na2CO3 (3 mL) and extracted with CH2Cl2 (3×15 
mL). The combined extracts were dried (MgSO4) and the solvent was removed under 
reduced pressure. The crude residue was purified using FCC over silica gel using a 
gradient of 10:90−40:60 EtOAc/petrol to give 20 as a white solid and as a single 
diastereoisomer (25 mg, 54%); Rf: 0.50 (30:70, EtOAc/petrol); [α]
25
D  +48 (c 0.3, 
CHCl3); IR vmax (cm
-1): 3000, 1639, 1476, 1035, 726; 1H NMR δ 7.30 (bs, 2H), 6.28 (bs, 
2H), 6.02 (bs, 2H), 4.75 (d, 2H, J 3.1 Hz), 4.03−3.95 (m, 2H), 3.81−3.71 (m, 2H), 
3.30−3.20 (m, 2H), 2.63 (t, 4H, J 7.2 Hz), 2.62−2.52 (m, 2H), 2.32−2.22 (m, 2H), 
2.20−2.10 (m, 2H), 2.00−1.85 (m, 4H), 1.85−1.75 (m, 2H); 13C NMR δ 169.6 (2), 155.4 
(2), 141.1 (2), 110.4 (2), 105.2 (2), 80.9 (2), 68.9 (2), 43.2 (2), 29.0 (2), 25.8 (2), 25.7 
(2), 22.9 (2); HRMS (ESI +ve) calculated for C24H31N2O6 (M+H
+) 443.2177, found 
443.2196. 
4.7 (3S)-1-(3-(Furan-2-yl)propyl)-6-oxopiperidine-2,3-diyl diacetate (2b). 
To a stirred solution of 2a (120 mg, 0.50 mmol) in pyridine (5 mL) was added acetic 
anhydride (0.20 mL, 2.00 mmol) and DMAP (6 mg, 0.05 mmol). The reaction mixture 
was stirred at rt for 16 h. The solvent was removed under reduced pressure and the 
residue was dissolved in EtOAc (15 mL) and washed with a saturated solution of CuSO4 
(3 × 15 mL). The solution was dried (MgSO4) and the solvent was removed under 
reduced pressure. The residue was purified by FCC over silica gel using a gradient of 
0:100−30:70 EtOAc/petrol to give 2b as thick colourless oil (158 mg, 98%); Rf: 0.55 
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(20:80, EtOAc/petrol); [α] 25D
 +69 (c 0.5, CHCl3);  IR vmax (cm
-1): 3000, 1746, 1666, 
1369, 1210, 1184, 1013, 937, 748, 740, 732;  1H NMR δ 7.29 (bs, 1H), 6.27 (t, 1H, J 2.4 
Hz), 6.07 (bs, 1H), 6.01 (d, 1H, J 2.9 Hz), 5.01 (q, 1H, J 3.2 Hz), 3.80−3.71 (m, 1H), 
3.16−3.06 (m, 1H), 2.64 (t, 2H, J 7.5 Hz), 2.61−2.45 (m, 2H), 2.30−2.20 (m, 1H), 2.10 
(s, 3H), 2.08 (s, 3H), 2.06-1.99 (m, 1H), 1.98−1.80 (m, 2H); 13C NMR δ 170.0, 169.8 
(2), 155.2, 141.2, 110.3, 105.2, 81.0, 67.2, 45.4, 27.4, 26.3, 25.3, 21.4, 21.1, 21.0; 
HRMS (ESI +ve) calculated for C16H22NO6 (M+H
+) 324.1456, found 324.1446. 
4.8 Macrocycle 21 
To a solution of 2a (100 mg, 0.418 mmol) in acetonitrile (3 mL) was added BF3·OEt2 
(0.052 mL, 0.418 mmol) and the reaction was stirred at rt for 2 d. The solvent was 
removed under reduced pressure and the dark brown residue was subjected to FCC over 
silica gel using a gradient of 0:100−25:90 MeOH/EtOAc to give 21 as light yellow solid 
and as a single diastereoisomer (54 mg, 29%); Rf: 0.32 (15:85, MeOH/EtOAc) Mp: 140–
145 °C (decomposed); [α] 25D +288 (c 0.3, MeOH); 
1H NMR (CD3OD) δ 6.53 (d, 2H, J 
5.9 Hz), 5.95 (d, 2H, J 5.9 Hz), 4.75 (d, 2H, J 13.1 Hz), 3.94-3.89 (m, 2H), 3.52 (d, 2H, 
J 2.7 Hz), 2.63−2.54 (m, 2H), 2.51−2.42 (m, 2H), 2.21 (dt, 2H, J 5.4, 17.5 Hz), 
2.04−1.95 (m, 2H), 1.91−1.77 (m, 4H), 1.77−1.59 (m, 4H);13C NMR (CD3OD) δ 170.9 
(2), 138.7 (2), 129.9 (2), 123.6 (2), 92.3 (2), 67.8 (2), 63.5 (2), 43.0 (2), 35.7 (2), 27.1 
(2), 26.5 (2), 21.3 (2); HRMS (ESI +ve) calculated for C24H31N2O6 (M+H
+) 443.2177, 
found 443.2184. 
4.9 Macrocycle 22. 
To a solution of 2b (60 mg, 0.185 mmol) in acetonitrile (3 mL) was added BF3·OEt2 
(0.023 mL, 0.185 mmol) and the reaction was stirred at rt for 16 h. The solvent was 
removed under reduced pressure and the dark brown residue was subjected to FCC over 
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silica gel using a gradient of 0:100−10:90 MeOH/EtOAc to give 22 as light yellow solid 
and as a single diastereoisomer (28 mg, 58%); Rf: 0.65 (10:90, MeOH/EtOAc) Mp: 123–
128 °C; [α] 25D  +473 (c 0.7, MeOH); IR vmax (cm
-1): 3000, 1739, 1634, 1473, 1362, 1240, 
1039, 748, 681; 1H NMR (CD3OD) δ 6.56 (d, 2H, J 6.1 Hz), 5.95 (d, 2H, J 6.1 Hz), 
5.06−5.02 (m, 2H), 4.76 (d, 2H, J 13.1 Hz), 3.74 (d, 2H, J 2.3 Hz), 2.67−2.57 (m, 2H), 
2.50−2.40 (m, 2H), 2.29 (dt, 2H, J 5.0, 17.3 Hz), 2.13−2.00 (m, 4H), 2.30 (s, 12H), 
1.99−1.73 (m, 4H), 1.69−1.60 (m, 2H); 13C NMR (CD3OD) δ 170.5 (2), 170.1 (2), 138.6 
(2), 129.5 (2), 123.7 (2), 92.2 (2), 66.9 (2), 64.6 (2), 42.7 (2), 35.4 (2), 27.0 (2), 23.6 (2), 
21.1 (2), 19.8 (2); HRMS (ESI +ve) calculated for C28H35N2O8 (M+H
+) 527.2388, found 
527.2376. 
4.10 Synthesis of macrocycle 21 from 22. 
To a solution of 22 (25 mg, 0.047 mmol) in MeOH (3 mL) was added KOH (26 mg, 
0.470 mmol) and the reaction mixture was stirred at rt for 16 h. The solvent was 
removed under reduced pressure and the crude residue was purified by FCC over silica 
gel using a gradient of 0:100−20:80 MeOH/EtOAc to give 21 as a light yellow solid (21 
mg, 98%). This compound was identical to that obtained above from cyclization of 2a.  
4.11 (S)-1-(3-(5-Bromofuran-2-yl)propyl)-3-hydroxypiperidine-2,6-dione (23). 
To a stirred solution of 19 (100 mg, 0.421 mmol) in DMF (5 mL) at 0 °C was added 
NBS (75 mg, 0.421 mmol) and the reaction mixture was stirred at the same temperature 
for 1 h. The reaction was quenched with a saturated solution of NaHCO3 (5 mL) and 
then extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water 
(3 × 20 mL) and then dried (MgSO4). The solvent was removed under reduced pressure 
and the residue was subjected to FCC over silica gel using a gradient of 10:90−30:70 




 −38.6 (c 0.3, CHCl3); IR vmax (cm
-1): 3434, 1722, 1658, 1363, 
1168, 1147, 1122, 1077, 1036, 796; 1H NMR δ 6.14 (d, 1H, J 3.4 Hz), 5.98 (d, 1H, J 3.4 
Hz), 4.16 (dd, 1H, J 12.5, 5.6 Hz), 3.86−3.71 (m, 2H), 2.87−2.80 (m, 1H), 2.64−2.53 (m, 
3H), 2.32−2.23 (m, 1H), 1.90−1.78 (m, 3H); 13C NMR δ 175.4, 171.5, 157.2, 119.5, 
111.9, 108.2, 68.5, 40.0, 30.9, 26.0, 25.8, 25.5; HRMS (EI +ve) calculated for 
C12H14Br
79NO4 (M
+·) 315.0101, found 315.0109. 
4.12 (5S)-1-(3-(5-Bromofuran-2-yl)propyl)-5,6-dihydroxypiperidin-2-one (24). 
The title compound was synthesised from 23 (100 mg, 0.31 mmol) using the method 
described for the synthesis of 2a. Compound 24 was isolated as a single diastereoisomer 
as a thick oil (75 mg, 75%); Rf: 0.43 (10:90, MeOH/EtOAc); [α]
25
D
 +31.8 (c 0.3, 
MeOH); IR vmax (cm
-1): 3536, 1613, 1489, 1288, 1125, 1039, 962, 781; 1H NMR 
(CD3OD) δ 6.24 (d, 1H, J 2.5 Hz), 6.12 (bs, 1H), 4.74 (bs, 1H), 3.87 (bs, 1H), 3.73−3.63 
(m, 1H), 3.29−3.19 (m, 1H), 2.66 (t, 2H, J 7.9 Hz), 2.62−2.50 (m, 1H), 2.30 (dd, 1H, J 
5.2, 17.6 Hz), 2.24−2.13 (m, 1H), 1.93 (p, 2H, J 7.5 Hz), 1.83−1.75 (m, 1H);13C NMR 
(CD3OD) δ 171.5, 157.9, 119.0, 111.7, 107.9, 83.6, 67.4, 44.7, 26.8, 25.9, 25.2, 22.2; 
HRMS (EI +ve) calculated for C12H16Br
79NO4 (M
+·) 317.0258, found 315.0263. 
4.13 (3S)-1-(3-(5Bromofuran-2-yl)propyl)-6-oxopiperidine-2,3-diyl diacetate (2c). 
Using the method described for the synthesis of 2b the title compound was isolated as 
colourless oil (59 mg, 78%); Rf: 0.55 (20:80, EtOAc/petrol); [α]
25
D  66.7 (c 0.7, CHCl3); 
IR vmax (cm
-1): 1745, 1665, 1369, 1211, 1154, 1125, 1057, 1012, 973, 940, 871, 785; 1H 
NMR δ 6.16 (d, 1H, J 3.0 Hz), 6.03 (bs, 1H), 6.00 (d, 1H, J 2.8 Hz), 5.03−4.97 (m, 1H), 
3.78−3.67 (m, 1H), 3.17-3.06 (m, 1H), 2.60 (t, 2H, J 7.3 Hz), 2.57−2.44 (m, 2H), 
2.30−2.19 (m, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.06−1.97 (m, 1H), 1.97−1.77 (m, 2H);13C 
NMR δ 170.0, 169.8 (2), 157.3, 119.6, 111.9, 108.2, 80.9, 67.2, 45.3, 27.4, 26.3, 25.5, 
24 
 
21.4, 21.1 (2); HRMS (EI +ve) calculated for C16H20Br
81NO6 (M
+·) 403.0449, found 
403.0450.  
4.14 (2R,6'S)-5,9'-Dioxo-1',2',3',6',7',8',9',9a'-octahydro-5H-spiro[furan-2,4'-
quinolizin]-6'-yl acetate (25). 
Method A: To a solution of 2c (50 mg, 0.124 mmol) in CH2Cl2 (5 mL) was added 
trifluoroacetic acid (0.028 mL, 0.374 mmol) and the reaction mixture was stirred at rt for 
16 h. The solvent was removed under reduced pressure and the residue was purified by 
FCC over silica gel using a gradient of 0:100–15:85 MeOH/EtOAc to give 25 as a white 
solid (19 mg, 54%). 
Method B: To a stirred solution of 2c (15 mg, 0.037 mmol) in acetonitrile (3 mL) was 
added scandium triflate (3.6 mg, 0.0074 mmol) and the reaction mixture was stirred at rt 
for 48 h. The solvent was removed under reduced pressure and the residue obtained was 
purified by FCC over silica gel using a gradient of 0:100–15:85 MeOH:EtOAc to give 
25 as a white solid (7 mg, 71%). 
Rf: 0.56 (10:90, MeOH/EtOAc);Mp: 195–200 °C; [α]
25
D  −20.0 (c 0.3, MeOH); IR vmax 
(cm-1): 1753, 1741, 1642, 1632, 1276, 1361, 1258, 1230, 1174, 1061, 1039, 917, 846; 1H 
NMR (CD3OD) δ 7.75 (d, 1H, J 5.6 Hz), 6.19 (d, 1H, J 5.6 Hz), 4.82−4.76 (m, 1H), 4.69 
(p, 1H, J 4.1 Hz), 4.01 (d, 1H, J 4.4 Hz), 2.69 (td, 1H, J 12.9, 4.9 Hz), 2.53−2.44 (m, 
1H), 2.37−2.29 (m, 1H), 2.05 (s, 3H), 2.02−1.94 (m, 1H), 1.89−1.66 (m, 4H);13C NMR 
(CD3OD) δ 172.4, 170.2, 170.0, 158.8, 120.8, 87.2, 65.9, 62.8, 42.5, 34.3, 27.4, 23.8, 
21.0, 19.7; HRMS (ESI +ve) calculated for C14H18NO5 (M+H
+) 280.1180, found 
280.1182. 
4.15 (S)-1-(3-(Furan-2-yl)propyl)-3-hydroxypyrrolidine-2,5-dione (26). 
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To a solution of 17 (500 mg, 4.00 mmol) in xylene (15 mL) was added L-malic acid 
(804 mg, 6.00 mmol) and the reaction mixture was heated at 180 °C for 2 h in a flask 
having a Dean-Stark water trap. The solvent was removed under reduced pressure and 
the residue obtained was purified by FCC over silica gel using a gradient of 20:80−55:45 
EtOAc/petrol to give 26 as a white solid (615 mg, 69%); Rf: 0.58 (25:75, EtOAc/petrol); 
Mp: 63–68 °C [α] 25D  −65.5 (c 0.9, CHCl3); IR vmax (cm
-1): 3513, 1700, 1406, 1341, 
1249, 1152; 1H NMR δ 7.28 (bs, 1H), 6.26 (dd, 1H, J 2.9, 1.8 Hz), 6.01 (d, 1H, J 2.9 
Hz), 4.60−4.55 (m, 1H), 3.58 (t, 2H, J 7.2 Hz), 3.02 (dd, 1H, J 18.1, 8.6 Hz), 2.68−2.59 
(m, 3H), 1.99−1.91 (m, 2H);13C NMR δ 178.7, 174.4, 154.6, 141.3, 110.4, 105.5, 67.0, 
38.7, 37.3, 25.8, 25.6; HRMS (ESI +ve) calculated for C11H14NO4 (M+H
+) 224.0918, 
found 224.0914. 
4.16 (S)-1-(3-(5-Bromofuran-2-yl)propyl)-3-hydroxypyrrolidine-2,5-dione (27). 
The title compound was synthesized from 26 (120 mg, 0.538 mmol) using the method 
described for the synthesis of 23 (115 mg, 71%); Rf: 0.58 (25:75, EtOAc/petrol); [α]
25
D  
+54.4 (c 0.6, CHCl3); IR vmax (cm
-1): 3457, 1697, 1439, 1405, 1344, 1150, 1124, 1011; 
1H NMR δ 6.17 (d, 1H, J 3.2 Hz), 6.02 (d, 1H, J 3.2 Hz), 4.60 (dd, 1H, J 8.1, 4.8 Hz), 
3.58 (t, 2H, J 6.7 Hz), 3.04 (dd, 1H, J 19.2, 9.1 Hz), 2.69−2.59 (m, 3H), 1.99−1.89 (m, 
2H);13C NMR δ 178.4, 174.2, 156.7, 119.8, 112.0, 108.5, 67.0, 38.5, 37.3, 25.8 (2); 
HRMS (EI +ve) calculated for C11H12Br
79NO4 (M
+) 300.9945, found 300.9943. 
4.17 (4S)-1-(3-(5-Bromofuran-2-yl)propyl)-4,5-dihydroxypyrrolidin-2-one (28). 
The title compound was synthesized from 27 (100 mg, 0.33 mmol) using the method 
described for the synthesis of 24 as a thick colourless oil (62 mg, 62%); Rf: 0.40 (10:90, 
MeOH/EtOAc); [α] 25D  +6.3 (c 0.5, MeOH); IR vmax (cm
-1): 3398, 1671, 1458, 1438, 
1124, 1065, 1012; 1H NMR (CD3OD) δ 6.25 (d, 1H, J 3.3 Hz), 6.12 (d, 1H, J 3.3 Hz), 
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4.93 (s, 1H), 4.08 (d, 1H, J 6.0 Hz), 3.53−3.45 (m, 1H), 3.29−3.21 (m, 1H), 2.82 (dd, 
1H, J 17.5, 6.2 Hz), 2.65 (t, 2H, J 8.0 Hz), 2.18 (dd, 1H, J 17.5, 1.5 Hz), 1.99−1.83 (m, 
2H);13C NMR (CD3OD) δ 174.7, 157.7, 119.1, 111.7, 108.0, 89.9, 71.2, 39.2, 38.2, 25.8, 
25.1; HRMS (ESI +ve) calculated for C11H15Br
79NO4 (M+H
+) 304.0179, found 
304.0186. 
4.18 (3S)-1-(3-(5-Bromofuran-2-yl)propyl)-5-oxopyrrolidine-2,3-diyl diacetate (29). 
The title compound was synthesized from 28 (60 mg, 0.154 mmol) using the same 
method used for the synthesis of compound 2b as a colourless oil (63 mg, 82%); Rf: 0.48 
(20:80, EtOAc/petrol); [α] 25D +52.3 (c 0.8, CHCl3); IR vmax (cm
-1): 1681, 1607, 1374, 
1466, 1233, 1071, 1041, 1012; 1H NMR 6.18 (d, 1H, J 3.0 Hz), 6.12 (s, 1H), 6.01 (d, 
1H, J 3.0 Hz), 5.12 (d, 1H, J 6.3 Hz), 3.62−3.53 (m, 1H), 3.19−3.10 (m, 1H), 2.92 (dd, 
1H, J 18.1, 6.2 Hz), 2.61 (t, 2H, J 7.6 Hz), 2.37 (d, 1H, J 18.1 Hz), 2.11 (s, 3H), 2.10 (s, 
3H), 1.99−1.79 (m, 2H);13C NMR δ 173.3, 170.2, 169.9, 157.0, 119.7, 111.9, 108.4, 
86.7, 71.1, 40.5, 36.1, 26.2, 25.5, 21.1, 21.0; HRMS (ESI +ve) calculated for 
C15H19Br
79NO6 (M+H
+) 388.0391, found 388.0387. 
 
4.19 (1'S,2R)-3',5-dioxo-2',3',5',6',7',8a'-hexahydro-1'H,5H-spiro[furan-2,8'-indolizin]-
1'-yl acetate (30). 
Compound 30 was synthesized from 29 (42 mg, 0.158 mmol) using the method (method 
A) described for synthesis of 25 (17 mg, 59%); Rf: 0.50 (10:90, MeOH/EtOAc); [α]
25
D  
−17.7 (c 0.1, MeOH); Mp: 172–178 °C; IR vmax (cm
-1): 1763, 1743, 1677, 1466, 1255, 
1231, 1183, 1039; 1H NMR (CD3OD) δ 7.70 (d, 1H, J 5.7 Hz), 6.26 (d, 1H, J 5.7 Hz), 
4.69 (dt, 1H, J 7.7, 1.5 Hz), 4.22−4.16 (m, 1H), 4.06 (d, 1H, J 1.3 Hz), 2.97−2.88 (m, 
1H), 2.74 (dd, 1H, J 18.2, 8.0 Hz), 2.39 (dt, 1H, J 18.3, 1.7 Hz), 2.23−2.11 (m, 1H), 2.01 
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(s, 3H), 1.80−1.68 (m, 3H);13C NMR (CD3OD) δ 172.1, 172.0, 170.6, 158.2, 121.5, 
86.8, 66.4, 66.3, 38.8, 37.2, 32.6, 20.3, 19.5; HRMS (ESI +ve) calculated for C13H16NO5 
(M+H+) 266.1023, found 266.1000. 
4.20 (E) and (Z)-3-(5-Bromofuran-2-yl)acrylonitrile (31).
21
 
To a solution of 15 (1.5 g, 12.6 mmol) in DMF (15 mL) at 0 °C was added NBS (2.23 g, 
12.6 mmol) under a N2 atmosphere and the reaction mixture was stirred at the same 
temperature for 1 h. The reaction was quenched by the addition of a saturated solution of 
NaHCO3 (5 mL) and extracted with EtOAc (3 × 50 mL). The combined extracts were 
dried (MgSO4) and the solvent was removed under reduced pressure. The crude residue 
was subjected to FCC over silica gel using a gradient of 0:100−10:90 EtOAc/petrol to 
give 31 as a thick colourless oil (1.77 g, 72%) and as a mixture of isomers (trans:cis = 
10:4.5); Rf: 0.52 (5:95, EtOAc/petrol); Trans isomer: 
1H NMR δ 6.96 (d, 1H, J 16.4 Hz), 
6.53 (d, 1H, J 3.5 Hz), 6.40 (d, 1H, J 3.5 Hz), 5.72 (d, 1H, J 16.4 Hz). Cis isomer: 1H 
NMR δ 7.05 (d, 1H, J 3.6 Hz), 6.85 (d, 1H, J 12.3 Hz), 6.45 (d, 1H, J 3.6 Hz), 5.20 (d, 
1H, J 12.3 Hz). 
4.21 (E)-3-(5-(Phenylthio)furan-2-yl)acrylonitrile (32). 
To a solution of 31 (1.00 g, 5.05 mmol) in methanol (20 mL) was added sodium 
thiophenolate (2.00 g, 15.1 mmol) and the reaction mixture heated at reflux for 16 h 
under a N2 atmosphere. Water (10 mL) was added and the mixture was extracted with 
EtOAc (3 × 50 mL). The combined extracts were dried (MgSO4) and the solvent was 
removed under reduced pressure. The crude residue was purified by FCC over silica gel 
using a gradient of 0:100−40:60 EtOAc/petrol to give 32 as a thick yellowish oil (791 
mg, 69 %) and as a mixture of isomers (trans:cis = 10:4.3); Rf: 0.38 (30:70, 
EtOAc/petrol); IR vmax (cm
-1): 2213, 1623, 1581, 1464, 1440, 1182, 1019, 950, 794; 
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Major isomer (trans):1H NMR δ 7.35 – 7.20 (m, 5H), 7.00 (d, 1H, J 16.3 Hz), 6.65 (d, 
1H, J 3.4 Hz), 6.60 (d, 1H, J 3.4 Hz), 5.73 (d, 1H, J 16.3 Hz); 13C NMR δ 152.7, 148.8, 
135.6, 134.0, 129.7, 129.6, 127.8, 120.2, 118.3, 117.1, 94.8; Minor isomer (cis): 1H 
NMR δ 7.29 – 7.15 (m, 5H), 7.13 (d, 1H, J 3.7 Hz), 6.88 (d, 1H, J 12.2 Hz), 6.69 (d, 1H, 
J 3.7 Hz), 5.22 (d, 1H, J 12.2 Hz); 13C NMR δ 152.8, 148.1, 134.7, 133.9, 130.1, 129.6, 
127.8, 119.8, 117.3, 116.8, 92.5; HRMS (ESI +ve) calculated for C13H10NOS (M+H
+) 
288.0478, found 228.0501. 
 
4.22 3-(5-(Phenylthio)furan-2-yl)propanenitrile (33). 
To a solution of 32 (500 mg, 2.20 mmol) in MeOH (10 mL) was added NiCl2.6H2O (52 
mg, 0.220 mmol) and Boc2O (959 mg, 4.40 mmol). The reaction mixture was cooled to 
0 °C followed by addition of NaBH4 (418 mg, 11.0 mmol) over 30 min. The reaction 
mixture was slowly warmed to rt and stirred at that tempertature for 16 h. A saturated 
solution of NaHCO3 was added and the reaction mixture was further extracted with 
EtOAc (3 × 25 mL). The combined extracts were dried (MgSO4) and the residue was 
purified by FCC over silica gel using a gradient of 0:100−45:55 EtOAc/petrol to give 33 
as a thick colourless oil (287 mg, 57%); Rf: 0.32 (30:70, EtOAc/petrol); IR vmax (cm
-1): 
2930, 1706, 1582, 1478, 1439, 1166, 1023, 792; 1H NMR δ 7.27−7.09 (m, 5H), 6.67 (d, 
1H, J 3.0 Hz), 6.26 (d, 1H, J 3.0 Hz), 2.99 (t, 2H, J 7.3 Hz), 2.67 (t, 2H, J 7.0 Hz); 13C 
NMR δ 155.7, 142.7, 136.4, 129.3, 127.6, 126.6, 121.1, 118.6, 109.6, 24.9, 16.6; HRMS 
(ESI +ve) calculated for C13H12NOS (M+H
+) 230.0635, found 230.0656. 
 
4.23 (S)-3-Hydroxy-1-(3-(5-(phenylthio)furan-2-yl)propyl)pyrrolidine-2,5-dione (35). 
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To a solution of lithium aluminium hydride (100 mg, 2.62 mmol) in Et2O (10 mL) at 0 
°C was added solution of 33 (200 mg, 0.873 mmol) in Et2O (3 mL) over 15 min. The 
reaction mixture was stirred at the same temperature for 1 h. The reaction mixture was 
quenched by the dropwise addition of water (2 mL) followed by addition of 10% NaOH 
solution (2 mL). The reaction mixture was diluted with Et2O (15 mL) and filtered 
through celite. The residue was washed with Et2O (4 × 10 mL). The filtrate was dried 
(MgSO4) and the solvent was removed under reduced pressure. The crude amine (34) 
obtained was used in next reaction without any further purification. Compound 35 was 
synthesized from amine 34 using the method described for the synthesis of 26 (110 mg, 
39% for 2 steps); Rf: 0.60 (20:80, EtOAc/petrol); [α]
25
D
 −22.24 (c 0.2, CHCl3). IR vmax 
(cm-1): 3405, 2922, 1695, 1582, 1439, 1347, 1148, 1024, 793. 1H NMR δ 7.27−7.20 (m, 
2H), 7.16−7.10 (m, 3H), 6.63 (d, 1H, J 2.9 Hz), 6.11 (d, 1H, J 2.9 Hz), 4.55 (dd, 1H, J 
4.8, 8.8 Hz), 3.56 (t, 2H, J 7.1 Hz), 3.00 (dd, 1H, J 8.0, 18.1 Hz), 2.65 (t, 2H, J 7.2 Hz), 
2.62 (dd, 1H, J 4.8, 18.1 Hz), 1.94 (p, 2H, J 7.0 Hz).13C NMR δ 178.2, 174.2, 159.2, 
141.1, 137.0, 129.3, 127.3, 126.4, 121.2, 108.2, 67.1, 38.6, 37.3, 26.2, 25.9. HRMS (ESI 
+ve) calculated for C17H18NO4S (M+H
+) 332.0952, found 332.0953. 
4.24 (4S)-4,5-Dihydroxy-1-(3-(5-(phenylthio)furan-2-yl)propyl)pyrrolidin-2-one (36). 
The title compound was synthesised from 35 (80 mg, 0.256 mmol) using the same 
method described for the synthesis of 2a (40 mg, 50%) and in a diastereomeric ratio of 
10:8;  IR vmax (cm
-1): 3340, 2936, 1662, 1582, 1439, 1260, 1110, 1066, 1024, 792; Major 
isomer: Rf: 0.55 (10:90, MeOH/EtOAc);
 1H NMR (CD3OD) δ 7.29-7.07 (m, 5H), 6.68 
(d, 2H, J 3.0 Hz), 6.24−6.19 (m, 1H), 4.90 (s, 1H), 4.06 (d, 1H, J 6.4 Hz), 3.52−3.40 (m, 
1H), 3.29−3.19 (m, 1H), 2.80 (dd, 1H, J 6.0, 17 Hz), 2.71−2.64 (m, 2H), 2.16 (dd, 1H, J 
2.0, 17 Hz), 2.00−1.82 (m, 2H); 13C NMR (CD3OD) δ 174.7, 160.1, 140.8, 137.2, 128.9, 
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126.8, 125.9, 120.8, 107.7, 89.9, 71.2, 39.3, 38.2, 25.9, 25.4; Minor isomer: Rf: 0.50 
(10:90, MeOH/EtOAc); 1H NMR (CD3OD) δ 7.29−7.07 (m, 5H), 6.68 (d, 2H, J 3.0 Hz), 
6.24−6.19 (m, 1H), 5.03 (d, 1H, J 5.3 Hz), 4.26−4.20 (m, 1H), 3.52−3.40 (m, 1H), 
3.29−3.19 (m, 1H), 2.54 (dd, 1H, J 6.8, 16.7 Hz), 2.71−2.64 (m, 2H), 2.34 (dd, 1H, J 
6.0, 16.7 Hz), 2.00−1.82 (m, 2H); 13C NMR (CD3OD) δ 173.9, 160.2, 140.8, 137.1, 
128.9, 126.9, 126.0, 120.8, 107.6, 83.4, 65.6, 39.5, 37.7, 25.8, 25.6; HRMS (ESI +ve) 
calculated for C17H20NO4S (M+H
+) 334.1108, found 334.1114. 
4.25 (3S)-5-Oxo-1-(3-(5-(phenylthio)furan-2-yl)propyl)pyrrolidine-2,3-diyl diacetate 
(37). 
The title compound was 37 synthesised from 36 (30 mg, 0.071 mmol) using the same 
method described for the synthesis of 2b (34 mg, 91%). and in a diastereomeric ratio of 
10:8; IR vmax (cm
-1): 2800, 1751, 1717, 1479, 1370, 1220, 1142, 1007, 964, 751; Major 
isomer: Rf: 0.65 (20:80, EtOAc/petrol); 
1H NMR δ 7.29−7.19 (m, 3H), 7.12 (t, 2H, J 7.3 
Hz), 6.64 (d, 1H, J 2.5 Hz), 6.11 (d, 1H, J 2.8 Hz), 6.0 (bs, 1H), 5.09 (d, 1H, J 6.3 Hz), 
3.60−3.50 (m, 1H), 3.19−3.09 (m, 1H), 2.89 (dd, 1H, J 6.7, 17.7 Hz), 2.63 (t, 2H), J 7.8 
Hz), 2.34 (d, 1H, J 17.7 Hz), 2.06 (s, 3H), 2.04 (s, 3H), 2.01−1.79 (m, 2H); 13C NMR δ 
173.3, 170.2, 169.9, 159.5, 140.9, 137.1, 129.2, 127.2, 121.1, 108.0, 86.8, 71.1, 40.5, 
36.0, 29.9, 26.1, 25.8, 21.0, 20.9; HRMS (ESI +ve) calculated for C21H23NO6SNa 




To a solution of 35 (50 mg, 0.151 mmol) in acetic acid (5 mL) was added hydrogen 
peroxide (30% solution in water, 0.5 mL) and the reaction mixture was stirred at rt for 2 
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d. A saturated solution of NaHCO3 (5 mL) was slowly added and the rmixture was 
extracted with EtOAc (3 ×20  mL). The extracts were dried (MgSO4) and the solvent 
was removed under reduced pressure. The crude residue was purified by FCC over silica 
gel using a gradient of 50:50−80:20 EtOAc/petrol to give 38 as a thick oil (52 mg, 96%); 
Rf: 0.43 (60:40, EtOAc/petrol); [α]
25
D
 −37.6 (c 2.0, CHCl3); IR vmax (cm
-1): 3443, 2942, 
1696, 1499, 1325, 1139, 1082, 1015, 752; 1H NMR δ 7.96 (d, 2H, 7.5 Hz), 7.60 (t, 1H, J 
7.5 Hz), 7.52 (t, 2H, J 8.0 Hz), 7.09 (d, 1H, J 3.7 Hz), 6.17 (d, 1H, J 3.3 Hz), 4.61−4.54 
(m, 1H), 3.53 (t, 2H, J 7.0 Hz), 3.01 (dd, 1H, J 8.4, 17.9 Hz), 2.64 (t, 2H, J 7.8 Hz), 
2.65−2.58 (m, 1H), 1.92 (p, 2H, J 7.1 Hz); 13C NMR δ 178.2, 174.2, 161.0, 148.2, 140.3, 
133.8, 129.5, 127.9, 118.9, 108.1, 67.0, 38.3, 37.3, 25.9, 25.4; HRMS (ESI +ve) 
calculated for C17H18NO6S (M+H
+) 364.0850 found 364.0850. 
4.27 (4S)-4,5-Dihydroxy-1-(3-(5-(phenylsulfonyl)furan-2-yl)propyl)pyrrolidin-2-one 
(39). 
The title compound was synthesized from 38 (50 mg, 0.137 mmol) using the method 
described for the synthesis of 26 (27 mg, 54%) and in a diastereomeric ratio of 10:0.7; 
IR vmax (cm
-1): 3310, 2954, 1653, 1447, 1320, 1140, 1058, 1018, 803; Major iomer: Rf: 
0.35 (15:85, MeOH/EtOAc); 1H NMR (CD3OD) δ 7.94 (d, 2H, J 7.8 Hz), 7.67 (t, 1H, J 
7.8 Hz), 7.59 (t, 2H, J 7.6 Hz), 7.18 (d, 1H, J 3.4 Hz), 6.32 (d, 1H, J 3.5 Hz), 4.87 (bs, 
1H), 4.05 (d, 1H, J 5.8 Hz), 3.46−3.37 (m, 1H), 3.26−3.17 (m, 1H), 2.79 (dd, 1H, J 6.2, 
17.5 Hz), 2.68 (t, 2H, J 7.5 Hz), 2.14 (d, 1H, J 17.6 Hz), 1.96−1.80 (m, 2H); 13C NMR 
(CD3OD) δ 174.8, 162.3, 148.0, 140.5, 133.7, 129.4, 127.4, 118.9, 107.8, 89.9, 71.2, 
39.2, 38.2, 25.5, 25.1; HRMS (ESI +ve) calculated for C17H20NO6S (M+H
+) 366.1006, 





The title compound was synthesised from 39 (25 mg, 0.055 mmol) using the same 
method described for the synthesis of 2b (30 mg, 98%); Rf: 0.40 (35:65, EtOAc/petrol);  
IR vmax (cm
-1): 2952, 1714, 1447, 1373, 1328, 1216, 1141, 1042, 1013, 964; 1H NMR δ 
7.98 (d, 2H, J 8.5 Hz), 7.61 (t, 1H, J 7.2 Hz), 7.54 (t, 2H, J 7.2 Hz), 7.11 (d, 1H, J 3.8 
Hz), 6.18 (d, 1H, J 3.4 Hz, 6.08 (bs, 1H), 5.11 (d, 1H, J 6.4 Hz), 3.59−3.48 (m, 1H), 
3.17−3.08 (m, 1H), 2.91 (dd, 1H, J 6.2, 18.0 Hz), 2.64 (t, 2H, J 7.6 Hz), 2.36 (d, 1H, J 
18.0 Hz), 2.09 (s, 3H), 2.07 (s, 3H), 1.98−1.78 (m, 2H); 13C NMR δ 173.3, 170.2, 169.9, 
161.3, 147.5, 140.0, 133.7, 129.4, 127.9, 118.9, 107.9, 86.6, 71.1, 40.4, 35.9, 25.8, 25.6, 
21.0, 20.9; HRMS (ESI +ve) calculated for C21H24NO8S (M+H
+) 450.1232, found 
450.1223.  
 
4.3 X-ray crystallographic study. 
4.3.1 Crystal data. 
Compound 25. C14H17NO5, M = 279.29, T = 200 K, orthorhombic, space group P212121, 
Z = 4, a = 5.6983(1), b = 9.3734(2), c = 25.0005(4) Å, V =1335.34(4) Å3, Dx = 1.389 g 
cm–3, 1804 unique data (θ = 2.6–27.5°), R = 0.029 [for 1650 with I > 2.0σ(I)]; Rw = 
0.074 (all data), S = 1.01. 
4.3.2. Structure determination.  
Images were measured on a Nonius Kappa CCD diffractometer (MoKα, graphite 
monochromator, λ = 0.71073 Å) and data extracted using the DENZO package.18 
Structure solution was by direct methods (SIR92).19 The structure was refined using the 
CRYSTALS program package.20 Atomic coordinates, bond lengths and angles, and 
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displacement parameters have been deposited at the Cambridge Crystallographic Data 
Centre (CCDC no. 840569). These data can be obtained free-of-charge via 
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by 
contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge 
CB2 1EZ, UK; fax: +44 1223 336033. 
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